Wolverine Trading’s Corvus Pharmaceuticals CRVS Stock Holding History

Wolverine Trading’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,688	Closed	-$8K	–	4148
2022 Q3	$8K	Buy	+10,688	New	+$10.2K	﹤0.01%	4464

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Wolverine Trading's CRVS Position: Q4 2022 in Review

Wolverine Trading sold out of Corvus Pharmaceuticals (CRVS) in Q4 2022, closing a stake of 10,688 shares — an estimated $8K sold.

Wolverine Trading first reported a position in CRVS in Q3 2022 and held it in 1 quarter. The position peaked at $8K in Q3 2022. 41 funds tracked by Wall St. Rank hold CRVS as of Q4 2022.

Wolverine Trading reported no remaining Corvus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Wolverine Trading sold 10,688 Corvus Pharmaceuticals shares in Q4 2022, an estimated $8K.
Wolverine Trading first reported a position in Corvus Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Wolverine Trading's Corvus Pharmaceuticals position peaked at $8K in Q3 2022.
41 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2022.

Based on Wolverine Trading's 13F filing for Q4 2022, filed 14 Feb 2023.